#USA #San Diego #Nivolumab #melanoma #HBI-8000

HUYABIO International Achieves Significant Phase 3 Results in Advanced Melanoma

HUYABIO International has made a groundbreaking announcement regarding its global Phase 3 clinical trial targeting advanced melanoma. This study evaluated the effectiveness of HBI-8000 in conjunction with nivolumab, a well-known immunotherapy drug. The trial has successfully demonstrated statistically significant improvements in patient outcomes, particularly in progression-free survival (PFS).

Key Findings

The results reveal a median PFS of 11.7 months for patients treated with the combination of HBI-8000 and nivolumab, which starkly contrasts with the 7.4 months median PFS for patients who received nivolumab and a placebo. This represents an impressive 58% increase in survival duration for those using the new combination therapy. Such results position HBI-8000 as a promising new treatment option for patients grappling with one of the most dangerous forms of skin cancer – melanoma.

The Phase 3 trial involved 404 participants across 15 countries, marking HUYABIO’s largest oncology study to date. This indicates a significant investment in research and underscores the global recognition of the urgency in finding effective treatments for melanoma.

About HBI-8000

HBI-8000 is an oral medication that has already secured regulatory approval for lymphoma treatment in China and Japan. With over 90,000 patients having used this drug, its safety profile is well-established, further boosting confidence among healthcare providers looking for innovative melanoma therapies. HUYABIO emphasizes that although immunotherapies like nivolumab have transformed melanoma treatment landscapes, there remains a considerable need for more effective options to cater to the diverse patient population.

Dr. Mireille Gillings, the CEO and Executive Chair of HUYABIO, expressed enthusiasm over the trial results and emphasized the importance of HBI-8000 in advancing melanoma treatment. 'These results represent an exciting milestone for patients and the future of melanoma treatment,' she stated, underlining the ongoing quest to enhance patient outcomes in this challenging field.

Future Steps

As the industry awaits further statistical analysis, which will delineate the full extent of HBI-8000’s effectiveness, HUYABIO plans to present the comprehensive data from the HBI-8000-303 trial at upcoming medical meetings. This will serve to inform and engage the medical community on the potential of this combination therapy in changing treatment paradigms.

HUYABIO’s Vision

HUYABIO International stands at the forefront of accelerating the global development of innovative biopharmaceutical products originating from China. By enabling cost-effective and lower-risk drug development across international markets, the company collaborates with biopharmaceutical firms and academic institutions to build a robust portfolio of China-sourced compounds spanning all therapeutic areas. Its offices in the US, Japan, and China underscore its commitment to fostering global partnerships dedicated to expediting product development.

For more information about HUYABIO International's research and innovations, visit www.huyabio.com. This new combination therapy for advanced melanoma promises not only to elevate treatment standards but also to provide renewed hope to patients and their families worldwide.